The
Latest
The Latest
News
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
News
PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
News
Wellbeing Subsidiary KGK Science Announces Successful Results of UP446, a Nutraceutical Ingredient, in Positive Immune Defense Response
News
Awakn Life Sciences Announces Signing of Lease for Second Clinic in Norway
More Articles
FEATURED
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
News
Wellbeing Subsidiary KGK Science Submits CTA for Phase IIA Clinical Trial
News
Filament Health Announces New United States Patent Issuances
Trending
#
Spotlight
Christopher J. Moreau | Chief Executive Officer, Algernon Pharmaceuticals
#
News
Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study
#
News
Mindset Pharma and PharmAla Biotech Enter into Exclusive Sales Agreement
#
News
Wellbeing Subsidiary Mindscape Treats its 1,000th Patient
#
News
Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis
Companies
#
ATAI Life Sciences
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Compass Pathways
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Algernon Pharmaceuticals
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Mind Medicine (MindMed)
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
#
Cybin Inc.
NEO
NASDAQ
CSE
TSXV
Private Company
Non-Profit
Features
News
Cybin Presents CYB003 Preclinical Data at 2022 American College of Neuropsychopharmacology Annual Meeting
News
BetterLife Announces Closing of Private Placement
News
Ehave Shareholder from CEO Ben Kaplan and Corporate Update
News
PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent Portfolio
© year Psychedelic Finance